Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Zhengjun Qiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8318-847X; OpenAlex author ID A5103269758. Sources: OpenAlex.

Their work

Papers
27 (first author 2, last author 21)
Trials
0
Grants
0
Labs led
2
Collaborators
36
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 27

  1. A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for Chemo-Immunotherapy of Pancreatic Ductal … Co-author DOI 10.1002/advs.76478↗
  2. Targeting OAS3 for reversing M2d infiltration and restoring anti-tumor immunity in pancreatic cancer. Last author DOI 10.1007/s00262-024-03898-w↗
  3. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. Last author DOI 10.1186/s12885-023-11239-w↗
  4. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). Last author DOI 10.1016/j.yexcr.2022.113402↗
  5. Long noncoding RNA negative regulator of antiviral response contributes to pancreatic ductal adenocarcinoma progression via targeting miR-299-3p. Last author DOI 10.3748/wjg.v28.i35.5141↗
  6. Correction to "Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression … Last author DOI 10.4251/wjgo.v14.i10.2085↗
  7. M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2. Last author DOI 10.1016/j.ymthe.2020.11.024↗
  8. Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis. Last author DOI 10.3748/wjg.v27.i17.1993↗
  9. Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT ax… Last author DOI 10.4251/wjgo.v13.i11.1709↗
  10. Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer. Last author DOI 10.1016/j.omtn.2020.08.021↗
  11. Tumor-Infiltrating Leukocyte Compositions and Prognostic Immune-Related Genes in Pancreatic Cancer. Last author DOI 10.21203/rs.3.rs-119677/v1↗
  12. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. Last author DOI 10.3748/wjg.v26.i19.2349↗
  13. Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. Last author DOI 10.3892/ol.2020.11300↗
  14. miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer. Last author DOI 10.1016/j.yexcr.2018.05.013↗
  15. Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. Last author DOI 10.1158/0008-5472.can-17-3841↗
  16. Krüppel-Like Factor 4 Inhibits Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis by Down-Regulating Caveolin-1 Expression. Co-author DOI 10.1159/000488426↗
  17. Downregulation of the N-myc downstream regulated gene 1 is related to enhanced proliferation, invasion and migration of pancreatic cancer. Last author DOI 10.3892/or.2017.5355↗
  18. Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN. Last author PMID 28469793↗
  19. SMAD4 and its role in pancreatic cancer. Last author DOI 10.1007/s13277-014-2883-z↗
  20. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Last author DOI 10.18632/oncotarget.4124↗
  21. Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. Last author DOI 10.1007/s10620-013-2841-4↗
  22. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.humpath.2012.04.014↗
  23. Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. Last author DOI 10.3892/or.2013.2576↗
  24. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. First author DOI 10.1158/0008-5472.can-11-3102↗
  25. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10620-010-1416-x↗
  26. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Co-author DOI 10.3892/ijo.2011.1000↗
  27. The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Last author DOI 10.4149/neo_2011_05_396↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zengya Guo · 9 shared papers, 2020–2023 · strength 1.36
  2. Yuhan Yang · 8 shared papers, 2020–2023 · strength 1.16
  3. Chen Huang · 11 shared papers, 2011–2023 · strength 0.81
  4. Buwei Teng · 5 shared papers, 2020–2022 · strength 0.70
  5. Haitao Gu · 3 shared papers, 2022–2024 · strength 0.56
  6. Kun-Dong Zhang · 3 shared papers, 2020–2022 · strength 0.46
  7. Xiaofeng Wang · 4 shared papers, 2018–2021 · strength 0.44
  8. Guangtao Luo · 4 shared papers, 2017–2020 · strength 0.43
  9. Gang Cen · 5 shared papers, 2015–2020 · strength 0.39
  10. Peng Cao · 2 shared papers, 2021–2023 · strength 0.28
  11. Jiang Long · 1 shared paper, 2026 · strength 0.26
  12. Tingting Kong · 1 shared paper, 2026 · strength 0.26
  13. Yan Zheng · 1 shared paper, 2026 · strength 0.26
  14. Xiang Xia · 3 shared papers, 2015–2018 · strength 0.21
  15. Shaopeng Zhang · 1 shared paper, 2024 · strength 0.21
  16. Hai‐Quan Wang · 1 shared paper, 2022 · strength 0.20
  17. Zhanshan Wang · 1 shared paper, 2020 · strength 0.19
  18. Bin Wang · 1 shared paper, 2021 · strength 0.17
  19. Xuan Han · 1 shared paper, 2023 · strength 0.16
  20. Weiwei Chen · 1 shared paper, 2020 · strength 0.11
  21. Zhonglin Zhu · 1 shared paper, 2018 · strength 0.08
  22. Jin Dou · 1 shared paper, 2018 · strength 0.08
  23. Jing Zhang · 1 shared paper, 2018 · strength 0.08
  24. Xiu-Hong Lv · 2 shared papers, 2011–2013 · strength 0.07
  25. Guanghui Zhu · 2 shared papers, 2011–2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.